The Risk-Based Validation Revolution: From Documentation Overload to Intelligent Compliance

The validation burden is changing forever—globally. The FDA's September 2025 Computer Software Assurance (CSA) guidance marks a landmark convergence with international standards, bringing U.S. regulations into alignment with the EU's Annex 11 risk-based approach that has long emphasized 'patient safety, data integrity, and product quality'. This convergence marks a fundamental shift away from traditional IQ/OQ/PQ documentation toward intelligent, risk-based approaches that focus on software being "fit for its intended use”.

For quality leaders in life sciences organizations, this creates both opportunity and urgency—opportunity to escape the weeks or months of validation work, and urgency to adopt compliant approaches before auditors in raise the bar.

This practical session reveals how forward-thinking pharma and medical device companies worldwide are leveraging risk-based frameworks to transform validation from a compliance burden into a strategic advantage, all while dramatically reducing time-to-market. Learn why MasterControl's patented validation approach achieved zero regulatory findings across thousands of customers globally since 2017—six years before the FDA formalized this methodology.

Following the presentation, our 15-minute demonstration will showcase MasterControl's game-changing Validation Excellence Tool (VxT) and Validation on Demand (VoD)—the only patented validation technologies that reduce validation from weeks or months to an average of 45 minutes while meeting both U.S. and EU regulatory expectations.